Small Molecule Inhibitors: Precision Tools Targeting Oncogenic Pathways for Therapeutic Intervention in Cancer

Cancer treatment has evolved significantly, with the integration of various therapeutic strategies aimed at eradicating cancer cells, managing the disease, and improving patients’ quality of life. While traditional treatments such as surgery, chemotherapy, radiation, and immunotherapy remain vital, newer approaches like precision medicine have revolutionized cancer therapy by focusing on personalized care. Small molecules have emerged as key agents in this field, offering specific targeting capabilities with improved pharmacokinetics, flexibility, and the ability to penetrate cellular barriers. Their development, particularly in the form of orally active drugs, offers considerable benefits over macromolecular therapies. Since the approval of imatinib, small molecules have become essential tools in targeting various proteins and pathways involved in cancer progression, with nearly 89 FDA-approved small molecule drugs available for cancer treatment. This growing body of research underscores the critical role of small molecules in improving cancer therapy outcomes.